ALT vs. KALV, VERV, TVTX, LRMR, OCS, STTK, CMPS, ANL, ABUS, and ATXS
Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include KalVista Pharmaceuticals (KALV), Verve Therapeutics (VERV), Travere Therapeutics (TVTX), Larimar Therapeutics (LRMR), Oculis (OCS), Shattuck Labs (STTK), COMPASS Pathways (CMPS), Adlai Nortye (ANL), Arbutus Biopharma (ABUS), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Altimmune (NASDAQ:ALT) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.
Altimmune presently has a consensus target price of $17.25, suggesting a potential upside of 134.06%. KalVista Pharmaceuticals has a consensus target price of $25.00, suggesting a potential upside of 108.33%. Given Altimmune's higher probable upside, equities analysts clearly believe Altimmune is more favorable than KalVista Pharmaceuticals.
Altimmune has higher revenue and earnings than KalVista Pharmaceuticals. Altimmune is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Altimmune had 35 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 39 mentions for Altimmune and 4 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.47 beat Altimmune's score of 0.16 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.
KalVista Pharmaceuticals has a net margin of 0.00% compared to Altimmune's net margin of -22,645.37%. Altimmune's return on equity of -46.96% beat KalVista Pharmaceuticals' return on equity.
KalVista Pharmaceuticals received 281 more outperform votes than Altimmune when rated by MarketBeat users. Likewise, 73.93% of users gave KalVista Pharmaceuticals an outperform vote while only 69.57% of users gave Altimmune an outperform vote.
Altimmune has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
78.1% of Altimmune shares are owned by institutional investors. 4.1% of Altimmune shares are owned by company insiders. Comparatively, 12.3% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Altimmune and KalVista Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Altimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Altimmune Competitors List
Related Companies and Tools
